# Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

> **NCT01905657** · PHASE2,PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1034 (actual)

## Conditions studied

- Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01905657
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-09
- **Primary completion:** 2015-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 1034 (ACTUAL)
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01905657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01905657, "Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01905657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*